Kim Ryalls

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Scott A. Prentice, Tom Michael Mitchell, Deborah A. Gilliam, 2017 .

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Matthew A. Wiles, Manisha, Christopher M. Horvat, 2021, Intensive Care Medicine.

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Scott A. Prentice, Jessica M. Powell, Sharon L. Burns, 2019, The Lancet.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Matthew A. Wiles, Nerissa C. Brown, Christopher M. Horvat, 2022, JAMA.

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Scott A. Prentice, Tom Michael Mitchell, Deborah A. Gilliam, 2018, Lancet.